185 related articles for article (PubMed ID: 15085919)
1. Development and validation of an instrument to measure the effects of a mistletoe preparation on quality of life of cancer patients: the Life Quality Lectin-53 (LQL-53) Questionnaire.
Kirchberger I; Wetzel D; Finger T
Qual Life Res; 2004 Mar; 13(2):463-79. PubMed ID: 15085919
[TBL] [Abstract][Full Text] [Related]
2. Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research.
Stauder H; Kreuser ED
Onkologie; 2002 Aug; 25(4):374-80. PubMed ID: 12232491
[TBL] [Abstract][Full Text] [Related]
3. Effects of a mistletoe preparation with defined lectin content on chronic hepatitis C: an individually controlled cohort study.
Huber R; Lüdtke R; Klassen M; Müller-Buscher G; Wolff-Vorbeck G; Scheer R
Eur J Med Res; 2001 Sep; 6(9):399-405. PubMed ID: 11669085
[TBL] [Abstract][Full Text] [Related]
4. [Value of mistletoe lectin standardized mistletoe extract for evaluating antitumor properties].
Mengs U; Witthohn K; Schwarz T; Lentzen H
Wien Med Wochenschr; 1999; 149(8-10):262-4. PubMed ID: 10483695
[TBL] [Abstract][Full Text] [Related]
5. [Lectin-related use of mistletoe: an experimental form of treatment with preclinically demonstrated potential risks].
Gabius S; Gabius HJ
Dtsch Med Wochenschr; 2002 Mar; 127(9):457-9. PubMed ID: 11870561
[No Abstract] [Full Text] [Related]
6. Induction of antibodies to viscotoxins A1, A2, A3, and B in tumour patients during therapy with an aqueous mistletoe extract.
Klein R; Classen K; Fischer S; Errenst M; Scheffler A; Stein GM; Scheer R; von Laue HB
Eur J Med Res; 2002 Aug; 7(8):359-67. PubMed ID: 12204844
[TBL] [Abstract][Full Text] [Related]
7. [Influence of ML-1 standardized mistletoe extract on the quality of life in head and neck cancer patients].
Steuer-Vogt MK; Bonkowsky V; Scholz M; Fauser C; Licht K; Ambrosch P
HNO; 2006 Apr; 54(4):277-86. PubMed ID: 16132877
[TBL] [Abstract][Full Text] [Related]
8. Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial.
Semiglazov VF; Stepula VV; Dudov A; Schnitker J; Mengs U
Anticancer Res; 2006; 26(2B):1519-29. PubMed ID: 16619567
[TBL] [Abstract][Full Text] [Related]
9. Cellular immunomodulation and safety of standardized aqueous mistletoe extract PS76A2 in tumor patients treated for 48 weeks.
Dohmen W; Breier M; Mengs U
Anticancer Res; 2004; 24(2C):1231-7. PubMed ID: 15154652
[TBL] [Abstract][Full Text] [Related]
10. [Blood and tissue eosinophilia, mistletoe lectin antibodies and quality of life in a breast cancer patient undergoing intratumoral and subcutaneous mistletoe therapy].
Kröz M; Schad F; Matthes B; Pickartz H; Girke M
Forsch Komplementarmed Klass Naturheilkd; 2002 Jun; 9(3):160-7. PubMed ID: 12119512
[TBL] [Abstract][Full Text] [Related]
11. Effects of a lectin- and a viscotoxin-rich mistletoe preparation on clinical and hematologic parameters: a placebo-controlled evaluation in healthy subjects.
Huber R; Klein R; Berg PA; Lüdtke R; Werner M
J Altern Complement Med; 2002 Dec; 8(6):857-66. PubMed ID: 12614536
[TBL] [Abstract][Full Text] [Related]
12. The Herdecke Questionnaire on Quality of Life (HLQ): validation of factorial structure and development of a short form within a naturopathy treated in-patient collective.
Ostermann T; Büssing A; Beer AM; Matthiessen PF
Health Qual Life Outcomes; 2005 Jul; 3():40. PubMed ID: 16004612
[TBL] [Abstract][Full Text] [Related]
13. Mistletoe compound enters clinical trials.
Habeck M
Drug Discov Today; 2003 Jan; 8(2):52-3. PubMed ID: 12565000
[TBL] [Abstract][Full Text] [Related]
14. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial.
Piao BK; Wang YX; Xie GR; Mansmann U; Matthes H; Beuth J; Lin HS
Anticancer Res; 2004; 24(1):303-9. PubMed ID: 15015612
[TBL] [Abstract][Full Text] [Related]
15. [The mistletoe myth--claims, reality and provable perspectives].
Gabius HJ; André S; Kaltner H; Siebert HC; von der Lieth CW; Gabius S
Z Arztl Fortbild (Jena); 1996 Apr; 90(2):103-10. PubMed ID: 8686332
[TBL] [Abstract][Full Text] [Related]
16. Measurement of the quality of life in cancer survivors.
Ferrell BR; Dow KH; Grant M
Qual Life Res; 1995 Dec; 4(6):523-31. PubMed ID: 8556012
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of immunoactive mistletoe lectin-I.
Beuth J
Anticancer Drugs; 1997 Apr; 8 Suppl 1():S53-5. PubMed ID: 9179369
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.
Schöffski P; Riggert S; Fumoleau P; Campone M; Bolte O; Marreaud S; Lacombe D; Baron B; Herold M; Zwierzina H; Wilhelm-Ogunbiyi K; Lentzen H; Twelves C;
Ann Oncol; 2004 Dec; 15(12):1816-24. PubMed ID: 15550588
[TBL] [Abstract][Full Text] [Related]
19. Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial.
Friess H; Beger HG; Kunz J; Funk N; Schilling M; Büchler MW
Anticancer Res; 1996; 16(2):915-20. PubMed ID: 8687151
[TBL] [Abstract][Full Text] [Related]
20. Mistletoe or not mistletoe is still the question.
Kiene H; Büschel G; Hornebar M
Forsch Komplementarmed Klass Naturheilkd; 2001 Oct; 8(5):309-12. PubMed ID: 11760713
[No Abstract] [Full Text] [Related]
[Next] [New Search]